Prelude Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Prelude Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$911K	Buy	+48,883	New	+$810K	0.07%	331
2025 Q4	–	Sell	-44,779	Closed	-$321K	–	1460
2025 Q3	$321K	Buy	+44,779	New	+$2.33M	0.03%	702
2024 Q2	–	Sell	-4,149	Closed	-$208K	–	1389
2024 Q1	$208K	Sell	4,149 -6,851	-62%	-$372K	0.01%	1088
2023 Q4	$664K	Buy	11,000 +4,600	+72%	+$237K	0.04%	410
2023 Q3	$365K	Buy	+6,400	New	+$353K	0.02%	583
2022 Q1	–	Sell	-50,000	Closed	-$495K	–	2073
2021 Q4	$495K	Hold	50,000	–	–	0.01%	1020
2021 Q3	$498K	Hold	50,000	–	–	0.01%	896
2021 Q2	$518K	Buy	+50,000	New	+$508K	0.02%	923

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's MLTX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 48,883 shares worth $911K. The stake represents 0.07% of the portfolio and ranks #331 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in MLTX as recently as Q3 2025.

Prelude Capital Management first reported a position in MLTX in Q2 2021 and has held it in 8 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Prelude Capital Management held 48,883 shares of MoonLake Immunotherapeutics worth $911K as of Q1 2026.
MoonLake Immunotherapeutics was a new Prelude Capital Management position in Q1 2026.
MoonLake Immunotherapeutics made up 0.07% of Prelude Capital Management's portfolio in Q1 2026, its #331 holding.
Prelude Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2021 and has held it in 8 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.